Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Pharmacogenomics of CNS Disorder Treatments
219
41. McCarthy MJ, Leckband SG, Kelsoe JR. Pharmacogenetics of lithium response in
bipolar disorder. Pharmacogenomics 2010;11:1439–1465.
42. Cacabelos R. Pharmacogenomics in Alzheimer’s disease. Mini Rev Med Chem 2002;​
2:59–84.
43. Cacabelos R. Pharmacogenomics for the treatment of dementia. Ann Med 2002;34:​
357–379.
44. Cacabelos R. The application of functional genomics to Alzheimer’s disease.
Pharmacogenomics 2003;4:597–621.
45. Cacabelos R. Pharmacogenomics and therapeutic prospects in Alzheimer’s disease.
Exp Opin Pharmacother 2005;6:1967–1987.
46. Cacabelos R. Pharmacogenomics and therapeutic prospects in dementia. Eur Arch
Psychiatry Clin Neurosci 2008;258:28–47.
47. Harold D, MacGregor S, Patterson CE, et al. A single nucleotide polymorphism in
CHAT influences response to acetylcholinesterase inhibition in Alzheimer’s disease.
Pharmacogenet Genomics 2006;16:75.
48. Noetzi M, Eap CB. Pharmacodynamic, pharmacokinetic, and pharmacogenetic aspects
of drugs used in the treatment of Alzheimer’s disease. Clin Pharmacokinet 2013;
52:225–241.
49. Ferraro TN, Buono RJ. The relationship between the pharmacology of antiepileptic
drugs and human gene variation: An overview. Epilepsy Behav 2005;7:18–36.
50. van der Weide J, Steijins LSW, van Weelden MJM, de Haan K. The effect of genetic
polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
Pharmacogenet Genomics 2001;11:287.
51. Chung WH, Hung SI, Hong HS, et al. Medical genetics: A marker for Stevens-Johnson
syndrome. Nature 2004;428:486.
52. Ferrell PB, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson
syndrome or toxic epidermal necrolysis. N Engl J Med 1995;33:1600–1608.
53. Comabella M, Fernandez-Arquero M, Rio J, et al. HLA class I and II alleles and
response to treatment with interferon-beta in relapsing-remitting multiple sclerosis.
J Neuroimmunol 2009;210:116–119.
54. Domanski P, Colamonici OR. The type-I interferon receptor. The long and short of it.
Cytokine Growth Factor Rev 1996;7:143–151.
55. Sriam U, Barcellos LF, Villoslada P, et al. Pharmacogenomic analysis of interferon
receptor polymorphisms in multiple sclerosis. Genes Immun 2003;4:147–152.
56. Byun E, Caillier SJ, Montalban X, et al. Genome-wide pharmacogenomic analysis
of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008;​
65:337–344.
57. Gilgun-Sherki Y, Djadetti R, Melamed E, Offen D. Polymorphism in candidate
genes: Implications for the risk and treatment of idiopathic Parkinson’s disease.
Pharmacogenomics J 2004;4:291–306.
58. Anton RF, Oroszi G, O’Malley S, Couper D, Swift R, Pettinati H, et al. An evaluation
of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment
of alcohol dependence: Results from the combined pharmacotherapies and behavioral
interventions for alcohol dependence (COMBINE) study. Arch Gen Psychiatry
2008;65:135–144.
59. Kim SG, Kim CM, Choi SW, Jae YM, Lee HG, Son BK, et al. A micro opioid receptor
gene polymorphism (A118G) and naltrexone treatment response in adherent Korean
alcohol-dependent patients. Psychopharmacology 2009;201:611–618.
60. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, et al.
A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone
response in alcohol-dependent patients. Neuropsychopharmacology 2003;​
28:1546–1552.